

**AFT Pharmaceuticals Limited**  
**(“Company”)**  
**Minutes of the 2021 Annual Meeting of Shareholders**

**Meeting date:** 6 August 2021  
**Meeting time:** 10.30am (New Zealand time)

---

<b>Present:</b>	Mr Flacks	Chairman
	Dr Atkinson	Chief Executive
	Mrs Atkinson	Executive Director
	Ms Baldauf	Non-Executive Director (on call and video presentation)
	Mr Burns	Non-Executive Director (on call and video presentation)
	Mr Lamb	Non-Executive Director
	Dr Wilson	Non-Executive Director
	Dr Witek	Non-Executive Director (on call and video presentation)
	Approximately	29 shareholders of the Company

---

#### **Introductions**

The Chairman, Mr Flacks, welcomed shareholders who had joined the meeting in person and via the webcast. He introduced the directors and senior management present at the meeting.

#### **Preliminary Matters**

The Chairman called the meeting to order. A necessary quorum being present, the meeting was deemed to be duly constituted and opened.

#### **Formal Addresses**

The Chairman formally addressed the meeting, providing a high-level overview of financial and operational performance for the year ended 31 March 2021 and outlining the company’s key strategic objectives to continue to maximise shareholder value. The Chairman outlined the Company’s growth strategy and its response to ongoing international Covid-19 government restrictions. The Chairman discussed the Company’s review of its corporate governance competencies and noted that the additions of Dr Witek and Ms Baldauf would broaden the Board’s skill set.

The Chief Executive, Dr Atkinson, provided an overview of AFT’s business and key products. He provided a detailed summary of operational and financial performance highlights during the 2021 financial period and explained how the Company had responded to the challenges of Covid-19. The Chief Executive provided shareholders with an update of the Company’s progress in each of its core markets and gave a broad summary of the Company’s research and development strategy.

## **Shareholder Questions and Discussion**

The Chairman invited shareholders to ask questions of the Board and management. Shareholders raised questions in relation to the Company's product range, its stock turnover, the Pascomer clinical trials and the allocation of the 2020 share purchase plan.

## **Formal Resolutions**

### ***Resolution 1: Auditor's Remuneration***

The Chairman confirmed that Deloitte had been reappointed auditor of AFT and its subsidiaries pursuant to the procedure set out in the Companies Act 1993.

After calling for any questions, the Chairman moved that the directors be authorised to fix the fees and expenses of Deloitte as auditor for the 2022 financial year.

### ***Resolution 2: Re-election of Mr David Flacks as a Director***

Mr Lamb confirmed that Mr Flacks re-election had the unanimous support of the Board.

Mr Flacks addressed the meeting in respect of his re-election.

After calling for questions, Mr Lamb moved the motion that Mr Flacks be re-elected a non-executive director of the Company.

### ***Resolution 3: Election of Ms Anita Baldauf as a Director***

The Chairman confirmed that Ms Baldauf's election had the unanimous support of the Board.

Ms Baldauf addressed the meeting through a pre-recorded video in respect of her election.

After calling for questions, the Chairman moved the motion that Ms Baldauf be elected a non-executive director of the Company.

### ***Resolution 4: Election of Dr Ted Witek as a Director***

The Chairman confirmed that Dr Witek's election had the unanimous support of the Board.

Dr Witek addressed the meeting through a pre-recorded video in respect of his election.

After calling for questions, the Chairman moved the motion that Dr Witek be elected a non-executive director of the Company.

## **Polls and Closure**

The Chairman advised that, as all other business had been concluded, polls would be conducted in respect of the resolutions put to shareholders at the meeting.


The conduct of the polls was administered by the share registrar, Computershare. The Chairman advised that the results of the polls would be released to NZX and the ASX later in the day.

The Chairman thanked shareholders for their attendance and interest in Company affairs.

The meeting ended at 12:01 pm.

Confirmed as a true and correct record of the meeting:

Signed:

A handwritten signature in dark ink, appearing to read "D. Flacks", written over a horizontal line.

David Flacks  
Chair